{Reference Type}: Journal Article
{Title}: Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma.
{Author}: Jiang J;Zhai R;Kong F;Du C;Ying H;
{Journal}: Eur Arch Otorhinolaryngol
{Volume}: 281
{Issue}: 1
{Year}: 2024 Jan 8
{Factor}: 3.236
{DOI}: 10.1007/s00405-023-08173-9
{Abstract}: <B>OBJECTIVE: </B>To assess the impact of body dose on survival outcomes in nasopharyngeal carcinoma (NPC) patients and to create novel nomograms incorporating body dose parameters for predicting survival.<BR><B>METHODS: </B>594 of non-metastasis NPC patients (training group, 396; validation group, 198) received intensity-modulated radiation therapy at our institution from January 2012 to December 2016. Patient characteristics, body dose parameters in dose-volume histogram (DVH) and hematology profiles were collected for predicting overall survival (OS) and progression-free survival (PFS). Nomograms for OS and PFS were developed using the selected predictors. Each nomogram was evaluated based on its C-index and calibration curve.<BR><B>RESULTS: </B>Body dose-based risk score for OS (RSOS), N stage, age, and induction chemotherapy were independent predictors for OS, with a C-index of 0.784 (95% CI 0.749-0.819) in the training group and 0.763 (95% CI 0.715-0.810) in the validation group for the nomogram. As for PFS, the most important predictors were the body dose-based risk score for PFS (RSPFS), N stage, and induction chemotherapy. C-index of PFS nomogram was 0.706 (95% CI 0.681-0.720) in the training group and 0.691 (95% CI 0.662-0.711) in the validation group. The two models outperformed the TNM staging system in predicting outcomes.<BR><B>CONCLUSIONS: </B>Body dose coverage is a useful predictor of prognosis in clinical routine patients. The novel nomograms integrating body dose parameters can precisely predict OS and PFS in NPC patients.